4.6 Article

Impaired High-Density Lipoprotein Function in Patients With Heart Failure

Journal

Publisher

WILEY
DOI: 10.1161/JAHA.120.019123

Keywords

cholesterol efflux; functionality; high‐ density lipoprotein; outcome; proteome

Funding

  1. European Commission [FP7-242209-BIOSTAT-CHF]
  2. EudraCT [2010-020808-29]

Ask authors/readers for more resources

In patients with heart failure, lower HDL cholesterol concentration has been identified as a strong predictor of adverse outcomes. Studies have shown that HDL function, particularly cholesterol efflux and anti-inflammatory capacity, may have significant impact on patient prognosis. Changes in HDL functionality, including decreased cholesterol efflux and anti-inflammatory capacity, were observed over a 9-month period in heart failure patients. It was also found that specific HDL proteins, such as apolipoprotein A1, are closely associated with HDL function metrics.
Background We recently showed that, in patients with heart failure, lower high-density lipoprotein (HDL) cholesterol concentration was a strong predictor of death or hospitalization for heart failure. In a follow-up study, we suggested that this association could be partly explained by HDL proteome composition. However, whether the emerging concept of HDL function contributes to the prognosis of patients with heart failure has not been addressed. Methods and Results We measured 3 key protective HDL function metrics, namely, cholesterol efflux, antioxidative capacity, and anti-inflammatory capacity, at baseline and after 9 months in 446 randomly selected patients with heart failure from BIOSTAT-CHF (A Systems Biology Study to Tailored Treatment in Chronic Heart Failure). Additionally, the relationship between HDL functionality and HDL proteome composition was determined in 86 patients with heart failure. From baseline to 9 months, HDL cholesterol concentrations were unchanged, but HDL cholesterol efflux and anti-inflammatory capacity declined (both P<0.001). In contrast, antioxidative capacity increased (P<0.001). Higher HDL cholesterol efflux was associated with lower mortality after adjusting for BIOSTAT-CHF risk models and log HDL cholesterol (hazard ratio, 0.81; 95% CI, 0.71-0.92; P=0.001). Other functionality measures were not associated with outcome. Several HDL proteins correlated with HDL functionality, mainly with cholesterol efflux. Apolipoprotein A1 emerged as the main protein associated with all 3 HDL functionality measures. Conclusions Better HDL cholesterol efflux at baseline was associated with lower mortality during follow-up, independent of HDL cholesterol. HDL cholesterol efflux and anti-inflammatory capacity declined during follow-up in patients with heart failure. Measures of HDL function may provide clinical information in addition to HDL cholesterol concentration in patients with heart failure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available